Deus/GEMS
This article was originally published in The Gray Sheet
Executive Summary
Deus Technologies will develop a new digital lung cancer detection system for use with GE Medical Systems' suite of digital radiography x-ray systems. Deus currently markets the RapidScreen RS-2000, the only FDA-approved device for early lung cancer detection, for use with analog x-ray (1"The Gray Sheet" July 30, 2001, p. 15). According to the terms of the deal, GE will have exclusive distribution rights to the new digital product...
You may also be interested in...
Deus RapidScreen Becomes First CAD To Gain FDA Approval For Lung Cancer
The integration of Deus Technologies' RapidScreen RS-2000 computer-aided diagnosis (CAD) software for lung cancer into Marconi Medical Systems' imaging devices could be facilitated by a recent U.S. distribution agreement between the companies.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.